7,744.75

-38.50

-0.49%

52,856.00

+160.00

+0.30%

29,523.25

-456.25

-1.52%

Russell 2000 Futures

2,849.20

+9.70

+0.34%

5.05

+0.05

+1.04%

16.91

-0.61

-3.48%

4,068.10

+16.50

+0.41%

79,863.38

-954.12

-1.18%

Crude Oil Dec 26

101.61

-1.17

-1.14%

US Private Equity

10,940.50

+9.00

+0.08%

We are experiencing some temporary issues. The market data on this page is currently delayed.

HKSE - Delayed Quote HKD

Ascletis Pharma Inc. (1672.HK)

5.355 -0.080 (-1.47%)

As of 10:05:59 AM GMT+8. Market Open.

Chart Range Bar

AlphaSpace Chart

Loading chart for 1672.HK

Previous Close 5.435
Open 5.460
Bid 5.340 x --
Ask 5.350 x --
Day's Range 5.340 - 5.650
52 Week Range 5.340 - 19.860
Volume 186,000
Avg. Volume 2,322,412
Market Cap (intraday) 5.63B
Beta (5Y Monthly) 0.43
PE Ratio (TTM) --
EPS (TTM) -0.660
Earnings Date --
Forward Dividend & Yield -- (0.00%)
Ex-Dividend Date --
1y Target Est 22.62

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Further, it offers ASC30, for obesity; ASC47 for muscle-preserving weight loss treatment; and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Ascletis Pharma Inc. was founded in 2013 and is based in Wan Chai, Hong Kong.

www.ascletis.com

217

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne

Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

1672.HK

53.03%

HANG SENG INDEX (^HSI)

9.75%

1-Year Return

1672.HK

41.60%

HANG SENG INDEX (^HSI)

12.20%

3-Year Return

1672.HK

195.86%

HANG SENG INDEX (^HSI)

32.95%

5-Year Return

1672.HK

96.88%

HANG SENG INDEX (^HSI)

8.85%

Analyst Price Targets

13.98

22.62 Average

5.355 Current

31.26 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

As of 10/26/2026

Market Cap

5.86B
Enterprise Value

3.25B
Trailing P/E

--
Forward P/E

--
PEG Ratio (current)

--
Price/Sales (ttm)

5.33k
Price/Book (mrq)

2.26
Enterprise Value/Revenue

3.07k
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-19.64%
Return on Equity (ttm)

-28.59%
Revenue (ttm)

947k
Net Income Avi to Common (ttm)

-591.6M
Diluted EPS (ttm)

-0.660

Balance Sheet and Cash Flow

Total Cash (mrq)

2.27B
Total Debt/Equity (mrq)

0.17%
Levered Free Cash Flow (ttm)

-362.7M

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Ascletis Pharma Inc.

5.355

-1.47%

Mkt Cap HKD 5.63B

Industry Biotechnology

HBM Holdings Limited

10.080

-0.10%

Mkt Cap HKD 8.769B

Industry Biotechnology

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

442.200

+1.98%

Mkt Cap HKD 105.696B

Industry Biotechnology

RemeGen Co., Ltd.

64.350

0.00%

Mkt Cap HKD 38.329B

Industry Biotechnology

Keymed Biosciences Inc.

68.200

+1.56%

Mkt Cap HKD 20.092B

Industry Biotechnology

Abbisko Cayman Limited

6.485

-2.11%

Mkt Cap HKD 4.645B

Industry Biotechnology

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

2.910

+3.37%

Mkt Cap HKD 1.248B

Industry Biotechnology

Ascentage Pharma Group International

28.800

0.00%

Mkt Cap HKD 10.758B

Industry Biotechnology

14.130

+3.21%

Mkt Cap HKD 34.991B

Industry Biotechnology

Pharmaron Beijing Co., Ltd.

26.500

-1.63%

Mkt Cap HKD 48.688B

Industry Biotechnology

Shanghai Junshi Biosciences Co., Ltd.

16.090

+0.19%

Mkt Cap HKD 16.506B

Industry Biotechnology

2552.HK Hua Medicine (Shanghai) Ltd.

2.280 +3.40%

1877.HK Shanghai Junshi Biosciences Co., Ltd.

16.090 +0.19%

2616.HK CStone Pharmaceuticals

4.810 +1.16%

1801.HK Innovent Biologics, Inc.

82.050 +0.98%

1873.HK Viva Biotech Holdings

1.290 -3.73%

Mobilize your Website

View Site in Mobile | Classic

Share by: